Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Preclinical studies evaluate Cz-007, Cz-008 and Cz-009 for treatment of Chagas' disease

Nov. 17, 2010

First oral anaphylatoxin C5a receptor antagonist CCX-168 is safe in phase I trial

Nov. 17, 2010

Abbott describes analgesic effects of A-1048400

Nov. 16, 2010

Suven Life Sciences presents SUVN-F90101 and SUVN-F91201

Nov. 16, 2010

Trans-sodium crocetinate is beneficial in PAD-related intermittent claudication

Nov. 16, 2010

TIGER-1 data detail potential of denufosol in cystic fibrosis

Nov. 16, 2010

Flt3L level in CSF is putative biomarker for primary fibromyalgia and Sjogren's syndrome

Nov. 15, 2010

Phase I/II trial shows safety of PfSPZ malaria vaccine in healthy volunteers

Nov. 15, 2010

Phase I/IIa trial evaluates prime-boost vaccination with AdCh63-MSP1 and MVA-MSP1 malaria vaccines

Nov. 15, 2010

Clinical data indicate RTS,S/AS01E malaria vaccine is safe in infants and children

Nov. 15, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...